Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAmelia MantioneDLDaniel J. LandsburgJCJordan S. Carter

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows shorter progression-free survival for large B-cell lymphoma post CART, indicating genomic profiling should guide next therapy choices.

Key Points

  • Progression-free survival following CART was generally short for large B-cell lymphoma patients, with a median of 3.88 months.
  • Genomic profiling revealed mutations associated with poorer outcomes, emphasizing the need for personalized approaches.
  • Bispecific antibodies were among subsequent therapies, demonstrating the variability in outcomes based on treatment choice.
  • This research indicates ongoing assessments of CART-cell persistence and mutation may benefit patient management planning.

Cite This Study

Mantione et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e26ehttps://doi.org/10.1182/blood-2025-5501
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience2025
  2. 2Real-world outcomes of autologous CD19-directed CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A single-center experience2025 · 1 citations
  3. 3Impact of sequencing of CART vs bi-specific antibody on survival in relapsed/refractory large B-cell lymphoma: An analysis from the ABC consortium2025 · 2 citations
  4. 4CD19 CAR T cell therapy is an effective strategy for first CNS relapse in pediatric b ALL2025 · 4 citations
  5. 5Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models2025